<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">Primary infection</z:e> with Epstein-Barr virus (EBV) is asymptomatic in children with immature immune systems but may manifest as <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, a vigorous immune activation, in adolescents or adults with mature immune systems </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">Infectious mononucleosis</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> immune activation are linked to increased risk for EBV-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we show that EBV initiates progressive lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by expression of BZLF-1 and the late lytic genes gp85 and gp350/220 in cord blood mononuclear cells (CBMC) but not in peripheral blood mononuclear cells (PBMC) from EBV-naive adults after <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> ex vivo </plain></SENT>
<SENT sid="3" pm="."><plain>Lower levels of proinflammatory cytokines in CBMC, used to model a state of minimal immune activation and immature immunity, than in PBMC were associated with lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Triggering the innate immunity specifically via Toll-like receptor-9 of B cells substantially suppressed BZLF-1 mRNA expression in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> ex vivo and in anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="5" pm="."><plain>This was mediated in part by IL-12 and IFN-gamma </plain></SENT>
<SENT sid="6" pm="."><plain>These results identify immune activation as critical factor for the suppression of initiation of lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We hypothesize that immune activation contributes to EBV-associated <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> by suppressing lytic EBV and in turn promotes latent EBV with transformation potential </plain></SENT>
</text></document>